In this paper, we propose and analyze a mathematical model for the treatment of chronic myelogenous (myeloid) leukemia (CML), a cancer of the blood. Our main focus is on the combined treatment of CML based on imatinib therapy and immunotherapy. Treatment with imatinib is a molecular targeted therapy that inhibits the cells involved in the chronic CML pathogenesis. Immunotherapy based on interferon alfa-2a (IFN-α) increases cancer cell mortality and leads to improvement of outcomes of the combined therapy. Interaction between CML cancer cells and effector cells of the immune system is modeled by a system of non-linear differential equations, where we introduced biologically motivated time-varying delays in the treatment terms. The analysis of the described system shows the existence of a unique global positive solution and a unique non-trivial equilibrium. We also derive explicit local and global stability conditions for the non-trivial equilibrium.
Introduction and biological motivation
Chronic myelogenous leukaemia (CML) is a progressive, malignant disease characterized by a large number of abnormal blood cells in the bone marrow and peripheral blood [, ] . The schematic progression in time of myelogenous leukemia is shown in Figure  .
The benefit of the treatment of CML with imatinib (Gleevec (Novartis International AG, Basel, Switzerland)) was first indicated in  [, ] . However, the loss of drug effectiveness was observed due to mutations of the target cancer cells, rendering the cells resistant to the drug [, ] . About  to % of patients do not respond to imatinib after prolonged therapy [, ] .
One of the early mathematical models of CML was a model created by [] . In all of these studies, the authors conclude that imatinib does not completely eliminate the leukemia cell population and propose that imatinib therapy should be combined with an additional form of treatment. http://www.advancesindifferenceequations.com/content/2012/1/217
Figure 1 A scheme of myelogenous leukemia progression in time. Myelogenous leukemia progresses through four distinct phases. After an initial period of 3-5 years the abnormal cell counts rise to a relatively steady state, called the chronic phase. At this stage the disease can be diagnosed. Several years of the chronic phase where the abnormal cell count oscillates with a period of the order of months are followed by a phase characterized by oscillatory instability (the acceleration phase). Ultimately, this leads to the usually fatal acute phase with sharp increase in the abnormal cell count. This is known also as the blast crisis [15] .
In this paper, we present a model that combines imatinib with the interferon alfa-α (IFN-α) immunotherapy. Including IFN-α treatment, we strengthen the immune response. We show that the immune response may play an important role in determining the length of time during treatment with imatinib for CML patients and would allow to keep the patient in the chronic stage for a longer period of time.
Recent data shows that IFN-α activation of immune cells (T killer cells, natural killer cells and others) contributes to the killing of cancer leukemic cells [, ] . Moreover, it is already proven that IFN-α may extend imatinib effect by activating immunological effector functions [] . Therefore, we assume that the combination treatment of imatinib and IFN-α immunotherapy can be a good candidate to improve the current CML therapy.
The mathematical description of the above model is described in Section . In Section  we discuss the existence of a positive and unique equilibrium and prove local and global stability of this equilibrium. Section  validates the model results using published data taken from in vitro, mouse and human studies.
Model description
The dynamics of the interaction between the immune system (effector T cells) and CML cancer cells in the body can be described by the following system of two ordinary nonlinear differential equations: 
We will analyze system () behavior under the following initial conditions:
Here, we assume that ϕ(t), where -θ ≤ t ≤  and ψ(t), where -τ ≤ t ≤  are nonnegative continuous functions where It is well known from the medical practice that the value of x(t) of the population of CML cells cannot be reduced to zero by treatment of any type, so the therapy can be called successful if the value of x(t) does not increase over time. Imatinib has a marked inhibitory effect on the value of x(t), while IFN-α add-on has an additional effect due to the stimulation of CML cell production. From mathematical standpoint, the role of the variable y(t) is to decrease the value of x(t).
We accounting for the behavior of the naive effector cells. Also, we added in the first equation the term accounting for the reduction in the number of cancer cells due to drug administration, while in the second equation we added the term describing the rate of increase in the number of immune cells that results from the treatment.
In our mathematical analysis of the above system, we aspire to stabilize the value of x(t) in such a way that x(t) does not exceed the limit of cancer CML cells in blood, which is characteristic of a chronic phase. The summary of values of the parameters used in the model is presented in Table . 3 The local and global stability of combined model for tumor immunotherapy
Positivity and uniqueness of solution system (1)-(2)
In this section we discuss the positivity and uniqueness of the solution (x(t), y(t)) of system ()-().
Lemma  [] Consider the initial value problem for a scalar linear delay equatioṅ
then u(t) > , t >  and for the solution of the inequalitẏ
one has v(t) ≥ u(t). http://www.advancesindifferenceequations.com/content/2012/1/217
. Then system ()-() has the unique global solution (x, y) such that
Proof System () can be presented in the following form:
where 
It is clear thatẋ(t  ) < , which allows us to obtain that x(t) ≤ K for t ≥ t  . Repeating the process of our reasoning, we prove that
The case x() = K is same as the case () if we replace the point t  = . Now, let us estimate y(t) behavior. Havinġ
we can state that
Denote z(t) = max -τ ≤ξ ≤t y(ξ ). Then
From the well-known Gronwall-Bellman inequality, we have
Hence, the inequalities in () hold for t ∈ [, c).
Suppose that c < ∞. Then there are only two possibilities: http://www.advancesindifferenceequations.com/content/2012/1/217
(a) lim t→c-x(t) = +∞ or lim t→c-y(t) = +∞; (b) lim t→c-x(t) =  or lim t→c-y(t) = . By inequalities (), x(t) and y(t) are bounded on any final interval. Then (a) is impossible.
By () relation lim t→c-y(t) =  is also impossible. Suppose now that lim t→c-x(t) = . There exists C >  such that  < y(t) < C, t ∈ [, c). Hence, the first equation in () implieṡ
Consider the following initial value problem:
After substitution w(t) = e -γ  Ct u(t), equation () has a forṁ u(t) = -ωγ  e -γ  C(t-h(t)) u h(t) . (  )
We have  ≤ t -h(t) ≤ θ . Hence
Lemma  and the inequality u(t) < u(), t <  imply that u(t) > , t ∈ [, c], then also w(t) > , t ∈ [, c]. Hence, there exists δ >  such that w(t) > δ, t ∈ [, c]. By Lemma  we have x(t) ≥ w(t) ≥ δ > , t ∈ [, c). This is a contradiction to the assumption lim t→c-x(t) = .
Hence, c = ∞ and the theorem is proven.
Theorem  If
there is the unique equilibrium (X * , ) of system () where X * = Ke
Proof It is obvious that (X * , ) is an equilibrium of system (). We have to prove the uniqueness only of this equilibrium or, in another words, we have to prove there is no other equilibrium (X  , Y  ), where
Suppose that (X  , Y  ), where X  > , Y  >  is the equilibrium of system (). Then, from the second equation in (), we have
Hence,
. http://www.advancesindifferenceequations.com/content/2012/1/217 Thus, we have
Then Y  <  contradicts our assumption and, therefore, system () has only one equilibrium (X * , ).
In the rest of the paper we assume that the conditions of Theorems  and  hold.
Local stability of the equilibrium (X * , 0)
To analyze local stability of the equilibrium (X * , ) for system (), we will use the lemma defined below. Consider the scalar linear equatioṅ
where
, lim t→∞ f (t) = , then for any solution x of (), lim t→∞ x(t) = .
Theorem  If
then the equilibrium (X * , ) is locally asymptotically stable.
Proof After substitution of x(t) = u(t) + X * , y(t) = v(t), system () can be rewritten in the following form:
The linearized system () has a form oḟ
The second inequality () implies that the second equation of () is exponentially stable. The first equation can be rewritten in the form (), where
By Lemma  lim t→∞ u(t) = . The theorem is proven.
Global stability of the equilibrium (X * , 0)
To analyze the global stability of the equilibrium (X * , ) for system (), we will use the following lemmas.
Lemma  []
Consider the scalar linear delay differential equatioṅ 
If a(t) ≥ a  > , |b(t)| ≤ qa(t),  < q < , then the solution of the above equation is asymptotically stable.

Lemma  [] Consider the following equation and inequalities:
where a, a k , k = , . . . , m are continuous bounded on
Denote by X(t, s) the fundamental function of equation (). Then X(t, s) > ,  ≤ s ≤ t. Moreover, for any t  , the equality x(t) = y(t) = z(t), t ≤ t  , implies y(t) ≤ x(t) ≤ z(t), t > t  ,
where x, y, z are the solutions of (), (), () respectively.
Let us formulate one of the classical results by Chaplygin [] (see also []).
Lemma  Consider the ODE and corresponding differential inequalities:
Theorem  If condition () holds, then for any solution (x, y) of system (), we have lim t→∞ x(t) = X * , lim t→∞ y(t) = , which means that (X * , ) is a global attractor for all solutions of system ()-().
Proof Suppose (x, y) is an arbitrary solution of (). From the second equation () we havė
By Lemma  we have  < y(t) ≤ u(t), where u is the solution of the equatioṅ
where u(t) = y(t), t ≤ . Lemma  implies that lim t→∞ u(t) = . Hence lim t→∞ y(t) = . The second part of the theorem is proven. In order to prove that lim t→∞ x(t) = X * , at first we will show thatẋ is a bounded function.
From the first equation (), we havė
Since lim t→∞ y(t) = , then  < y(t) < M y for some M y > . Thuṡ
and |ẋ(t)| ≤ C for some C > . Using all the above, we can rewrite the following:
Since lim t→∞ (t -h(t)) = , then for any > , there exists t  such that ωγ  C(t -h(t)) < , t ≥ t  . And therefore,
Consider now an ODE associated with the previous differential inequalitẏ where u(t  ) = x(t  ), and a functional equation F(p, ) = , where
We have F(X * For the solution of equation (), we haveu(t) > , 
We also havė
then for any > , there exists t  such thaṫ
Consider an ODĖ
Performing the same calculations as for equation (), we can show that for small > , equation () has the unique equilibrium q( ) such that lim → q( ) = X * . Hence, for any solution of equation (), we have lim t→∞ v(t) = q( ). By Lemma  we obtain
The theorem is proven. 
Simulation results
In order to verify the mathematical model of the biological system, it is widely accepted to estimate the conditions defined in the presented theorems based on the parameters set taken from the biological and medical literature (these parameters are taken from Table ) .
System () has an equilibrium (X * , ) where
Substituting the relevant parameters from Table  , we get that X * = . ×   exp(-×. . ) = ,, which means that the cancer cells number will not exceed the , cells at a constant daily dose of  mg imatinib.
With increasing the daily dose of imatinib to  mg, the amount of cancer cells decreases to almost ,. These numerical results are consistent with the data given in [] .
In order to check the local and global stability conditions, we substitute parameters to the expression in α × γ  + β  < μ y . The following numerical inequality is received:  × . + . ×  - < .. The obtained result supports that the model ()-() has a positive stable local and global equilibrium if condition () is satisfied.
Conclusion
In this work we have proposed a mathematical model for the combination treatment of chronic myelogenous leukemia with imatinib and IFN-α to overcome immune suppressive side effects of imatinib, prolonging the chronic phase of the disease. Our model consists of a system of two non-linear delay differential equations with logarithmic and rational nonlinearities. In order to describe the influence of two types of the treatment component (imatinib and IFN-α) on the model compartments, we introduced delays and explained a biological motivation for it. The proposed two-compartment model allows to evaluate directly the expected steady states of the system.
In our work we investigate the contribution of IFN-α (immunotherapy) in eliciting strong killer cells (CTL) responses against cancer (CML) cells in addition to imatinib therapy by examination of CTL and CML cells populations only. The dose of IFN-α has an inhibitory effect on the value of x(t), as seen from the formula (). As a result of calculations shown in Section , we observe that y(t) inhibits x(t), destroying itself to  in spite of constant addition of IFN-α.
The existence of unique global solutions for CML model was defined. Explicit local and global stability conditions for the unique non-trivial equilibrium were obtained by applying the method of delays in differential inequalities and linear stability theory of non-linear delay differential equations. The numerical results show that our model replicates the averaged behavior of the combined treatment.
In the future, in order to avoid resistance to imatinib, it looks reasonable to change the IFN-α to another type of the treatment in combination with imatinib [] . The best form of combination therapy that leads to improved survival in patients remains to be seen in future by mathematical models and clinical trials. http://www.advancesindifferenceequations.com/content/2012/1/217
